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THE MEASUREMENT of oestrogen recep-
tors (RE) in human breast tumours has
identified a group of patients with recep-
tor-negative (RE-) tumours who have a
very low response rate to hormonal mani-
pulation. In contrast 60% of patients
with receptor-positive (RE+) tumours
respond to endocrine treatment (McGuire
et al., 1975). It is clear that more accurate
identification of hormone-sensitive tu-
mours would allow better selection of
treatment than is possible at present, and
various additional measurements have
been suggested to help improve the posi-
tive predictive value of RE assays, such
as simultaneous measurement of pro-
gesterone receptor (RP) (Horwitz et al.,
1975). In addition to a role for endocrine
therapy, a recent survey has suggested
that RE measurements might also be
helpful in selecting patients for chemo-
therapy (Lippman et al., 1978). In this
report some of the clinical correlations
of cytosol RE and RP measurement are
presented, and methods of improving the
accuracy of receptor assays in selection of
patients for endocrine treatment are
assessed.
Clinical data were reviewed from 99
patients with metastatic breast cancer
treated at Auckland Hospital from August
1975 to August 1978 in whom receptor
assay information was available. Patients
received endocrine therapy (80 treatment
courses in 66 patients) chemotherapy (31
treatment courses in 29 patients), or a
combination ofboth (36 treatment courses
in 34 patients). Individual regimens of
endocrine therapy involved treatment
with tamoxifen (38 patients), aminoglu-
tethemide (24), androgens (6), oestrogens
(8) and oophorectomy (4). The response to
treatment was assessed using the objective
criteria of the British Breast Group (Hay-
ward et al., 1977). Thus disappearance of
all detectable disease was labelled "'com-
plete remission", and regression by at least
50% of at least half the detectable lesions
andwith nogrowth ofanylesion or appear-
ance of new disease was classed "partial
remission". Static disease was defined as
''no progress in any detectable lesion"
and "no appearance of new metastases"
when the disease had been advancing
before treatment was begun. Appearance
of a new site of disease, or growth in any
existing lesion, was labelled "progressive
disease". At least 3 months ofobservation
were required before a remission category
was assigned. The term "remission" refers
to those groups with complete remission,
partial remission or static disease. Com-
plete disappearance of bony abnormality
on X-ray was required before complete
remission of bone metastases was claimed.
In general, physical examinations and
clinical assessments were carried out at
3-monthly intervals, and total-body bone
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scintigramns and relevant X-rays com-
pleted at 6-monthly intervals; bone dis-
ease was confirmed by radiographs in all
cases. Clinical assessment was performed
by a panel using the patient's notes, rele-
vant X-rays and bone scintigrams. An
independent referee (E.P.A.) who did not
know the patients was included, and the
receptor status of the patients was not
disclosed during discussion.
Biopsy samples from metastatic sites
were measured for RE and RP as des-
cribed (Holdaway & Mountjoy, 1978), with
some recent assay modifications. Unlabel-
led steroids were added to tubes in 100%
ethanol and dried under an N2 stream;
labelled steroid was later added to cytosol
preparations in 2% ethanol, giving a final
ethanol concentration of 0.004%0. Re-
cently, tumour samples have been pre-
pared for assay by pulverization in the
frozen state with a stainless-steel pestle
and mortar, and the resultant powder
homogenized as previously described
(Holdaway & Mountjoy, 1978). A sig-
nificant amount ofreceptor was arbitrarily
defined as 5 fmol/mg cytosol protein or
more (RE) or 3 finol/mg cytosol protein
or more (RP). Statistical evaluation was
carried out by a non-parametric method,
the Wilcoxon rank sum test, and popula-
tion groups were compared using Fisher's
modification of Yates's chi-squared test
(Langley, 1968).
The frequency of objective response to
treatment is shown in Fig. 1. Patients
with RE+ tumours had a significantly
greater response rate overall to endocrine
therapy than those with RE- tumours.
The difference between the RE+ and
RE- groups remains significant, whether
or not patients with static disease are
included in the remission category.
Two of the three RE- patients who
responded to endocrine treatment were
pre-menopausal, and one of these
tumours was RP+, suggesting that this
was possibly a "false-negative RE" tu-
mour (see below). By comparison with the
results for endocrine treatment, there was
no significant difference in remission rate
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FIG. 1 Objecti\ e response of patients with
metastatic breast cancer to various treat-
ments. Endo =en(locrine therapy, clhemo =
chemotherapy, combined =endo. +cliemo.
* Significant difference (P < 0 002).
between RE+ and RE- tumours with
chemotherapy or combined endocrine
treatment and chemotherapy.
In 57 treatments in which both RE and
RP measurements were available, RP
assay did not improve the discrimination
between responding and non-responding
patient groups (Table I). In particular, the
response rate in the RE+ group was
equally divided between those tumours
which were RP+ and RP-. On one occa-
sion RP measurement provided useful
information in the single patient in the
series with a tumour which was RE-
RP+; this patient had a complete remis-
sion with tamoxifen therapy.
TABLE.-Oestrogen and progesterone recep-
tor status and response to treatment
Patients respon(Iiing/Patients treated
Treatment RE+ RP-t RE+ RP- RE- RP+ RE- RP-
Endocrine 4/6 9/12 1/1 2/15
Chlemo-
therapy 3/3 2/4 2/4
Combined 3/5 5/5 5/12
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FIG. 2. Concentration of oestro
(RE) in metastatic tumour fr
with breast cancer. 0 =patient
to endocrine therapy; 0 =1
responding to endocrine therap
RP+ tumour (responded t4
therapy). Dotted line =arbitf
significance of RE concentrati,
The influence of the tumc
tion of RE on response rate
therapy is shown in Fig. 2, 1
with the menopausal status
When the level of RE was >
all tumours responded to hc
ment, and the response rate
RE content >50 fmol/mg
significantly greater than in
of RE content between 5 ar
(13/24) (P<0.05). Thus t
chosen level of 5 fmol R
protein as "significant" doe
ably distinguish the majoril
ing from nonresponding pat
Tumour RE status also appears to
influence significantly the duration of re-
o mission with various treatments. With
8 endocrine therapy the duration ofresponse
00 in RE- responders was 4±+ 13 months
0Q (n= 3) compared to 10 + 5 7 months (n=
23) in RE+ responders (P < 0.05). A
0 similar significant advantage favouring
a RE+ (15 3 + 9 2 months, n=11) compared
with RE- (5 9 + 2.1 months, n= 7) pa-
40 tients was seen with combined endocrine
~ and chemotherapy (P < 0-002). In contrast,
with chemotherapy RE- patients (13.3 +
10 5 months, n = 8) had a longer duration
* of response than RE+ patients (5-1 + 4-4
months, n= 7) (P < 0 002). The significance
o was unaltered if patients with static
* disease were considered as not responding
to treatment. The site of disease did not
@000 significantly affect the response rate or the
* correlation of endocrine response with the
presence of RE, with the exception that
the rate of response of patients with
visceral metastases to endocrine therapy
was low. An analysis of the number of
sites involved in metastatic disease deter-
POST- mined clinically and radiologically did not
MENOPAUSAL show any significant difference between
RE+ and RE- groups or between respond- )gen receptor
rom patients ing and non-responding tumours.
tsresponding Retrospective analysis of the disease-
patients not free interval for the patient group (time
)y; x =RE-
o endocrine from initial mastectomy to the appearance
ary level of of recurrent disease, excluding patients
.on. with metastases at initial presentation)
showed that RE+ patients had experienced
ur concentra- a significantly longer disease-free interval
- to endocrine (37 + 28 months) than RE- patients
and compared (22.7 + 20 months) (P< 0 002).
)fthe patients. This study thus confirms, in a small
,100 fmol/mg, series of patients from a single centre, the
)rmonal treat- report of a multicentre retrospective
in tumours of analysis of receptor data in patients with
(10/13) was metastatic breast cancer (McGuire et al.,
those tumours 1975) which concluded that patients with
id 50 fmol/mg RE- tumours have a much lower response
he arbitrarily rate to endocrine therapy than those with
,E/mg cytosol RE+ tumours. In the present series, even
,s indeed suit- when RE- patients responded to endocrine
ty of respond- treatment the mean duration of remission
Dients. was very brief and treatment usually led
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to disease becoming static without sig-
nificant objective tumourregression. These
observations favour the theory that objec-
tive response to endocrine therapy in
RE- tumours probably results from a
response in a small proportion of RE+,
hormonally responsive cells in the tumour.
The presence of progesterone receptor
(RP) has been proposed as a means of
identifying tumours biologically sensitive
to oestrogen and hence as a method of
improving the discrimination of RE
measurements (Horwitz et al., 1975). How-
ever, in the present series it did not appear
that RP assays added significantly to the
discrimination of RE measurements, with
the exception of one RE- RP+ tumour.
From the present data such a tumour
should be classified as if RE+.
As a further means of improving the
positive predictive capacity of receptor
assays it has been suggested that tumours
with a high RE content arc particularly
likely to be hormone responsive (Heuson
et al., 1977). In the present study, when
the tumour RE content was > 50 fmol/mg
protein, about 80% of the patients res-
ponded to hormonal treatment (Fig. 2).
This observation thus indicates one
method of improving the accuracy of
prediction of hormonally responsive
tumours.
It has recently been claimed that pa-
tients with RE- metastatic tumours have
a significantly increased response rate to
chemotherapy compared with RE+ tu-
mours (Lippman et al., 1978). However,
discrepant reports have appeared (Kiang
et al., 1978). In the present series there was
no apparent difference in the rate of
response to chemotherapy between RE+
and RE- groups, although the total
number of patients treated was small. It
was striking, however, that the duration
ofremission in RE- patients responding to
treatment was significantly longer than in
responding RE+ patients. This may in part
support the contention of Lippman et al.
(1978), if, as they propose, chemotherapy
is more effective against the proportion of
tumours which are RE-.
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